Dr. Jonathan W. Said Joins CombiMatrix Molecular Diagnostics' Scientific Advisory Board
"CombiMatrix Molecular Diagnostics is a true innovator in the development of molecular cancer diagnostics," stated Dr. Said. "I look forward to working with this team and am very excited about the future of CMD."
“We are very pleased that Jonathan is joining CMD's Scientific Advisory Board to provide critical knowledge in the area of lymphoma molecular pathology”
"We are very pleased that Jonathan is joining CMD's Scientific Advisory Board to provide critical knowledge in the area of lymphoma molecular pathology," said Matthew Watson, CEO of CombiMatrix Molecular Diagnostics. "We look forward to his insight and leadership as we begin to launch our diagnostic services."
Dr. Said is a prominent expert in the field of molecular diagnostics, with a particular focus on lymphoma. He is active in the United States, Canadian, and International Academy of Pathology, American Society for Hematopathology, American Society of Hematology, and College of American Pathologists. He is a well-known lecturer and has authored and co-authored articles in many peer-review journals including American Journal of Pathology, American Journal of Clinical Pathology, Cancer, Human Pathology, and New England Journal of Medicine.
Dr. Said received his medical degree from the University of Witwatersrand Medical School, Johannesburg, South Africa. He completed his residencies in pathology at the Mallory Institute of Pathology and Peter Bent Brigham Hospital, Boston, Massachusetts. He served a fellowship in Hematopathology at Peter Bent Brigham Hospital and fellowships in clinical and research pathology at Harvard Medical School -- http://www.healthcare.ucla.edu/institution/physician?personnel_id=9317
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.
The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.
The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 34 patent portfolios, which include over 130 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, high resolution optics, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.
Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.
Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.